Table 1.

Clinical patient characteristics

Patient ID #CloneAgeGenderCD4/CD8 RatioAbsolute CD4 countTreatmentsDisease duration (y)
395Vβ1767M318,323I, TS, D, G, ECP3
326Vβ7.280M10.22,893I, ECP, B, A5
489Vβ13.246M17.81,991A, G1
414Vβ13.172M182,442ECP, TS, A, V, D, P, R, G0.5
478Vβ1756F7.182,546TS, ECP1
484Vβ256F9.432,383TS, ECP, SS2
279Vβ13.172M13.52,504D, B, ECP, PUVA, I, A, V, G,5
475Vβ270F3.11,230UVB, ECP, A7
382Vβ175F2.671,029TS, UVB9
372Vβ1764F9411,083PUVA, ECP, UVB, TS, I2
365Vβ1783M233,671B4
330Vβ13.172M18.65,028UVB, TS, B8
292Vβ1767M32.35,356PUVA, UVB, TS, I, ECP, B, G13
119Vβ13.178F14.52,800PUVA, D, I, ECP, V, B6
99Vβ1781F12.563,530PUVA, UVB, TS7
44Vβ1496F6.521,495I, SS16
472Vβ288M933,798ECP, B, PUVA, A3

Abbreviations: I, IFN-α2a; ECP, extracorporeal photochemotherapy; V, vorinostat; B, bexarotene, D, denileukin diftitox; TS, topical steroids; SS, systemic steroids; G, gemcitabine; A, alemtuzumab; P, pralatraxate; R, romidepsin; PUVA, psoralen + UVA treatment.